New drug combo trial aims to outperform standard for advanced colon cancer
NCT ID NCT06951503
Summary
This study is comparing a new drug combination (AK112 plus chemotherapy) against the current standard treatment (bevacizumab plus chemotherapy) for people newly diagnosed with metastatic colorectal cancer. It aims to see if the new combination is more effective at controlling the cancer and helping patients live longer. The trial will involve 560 participants and is currently recruiting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuanzhou, Guangdong, China
Contact
-
The Sixth Hospital,Sun Yat-sen University
RECRUITINGGuanzhou, Guangdong, 510000, China
Contact
Conditions
Explore the condition pages connected to this study.